Rheumatoid arthritis patients with low baseline Health Assessment Questionnaire scores have a risk of functional disability progression: a post hoc analysis of a nationwide longitudinal cohort in Japan.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 13 11 2019
accepted: 13 01 2020
pubmed: 9 9 2020
medline: 15 12 2020
entrez: 8 9 2020
Statut: ppublish

Résumé

To determine prognostic factors for the Health Assessment Questionnaire-Disability Index (HAQ-DI) progression in patients with rheumatoid arthritis (RA) in clinical practice. We evaluated 388 biological disease-modifying anti-rheumatic drug (bDMARD)-naïve Japanese patients with RA with moderate to high disease activity at study entry after being treated with conventional synthetic DMARDs. These patients were treated according to a treat-to-target (T2T) strategy for one year. The Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and the HAQ-DI were assessed every three months. We also evaluated joint destruction using a modified total Sharp score at baseline and at one year. HAQ-DI progression was defined as the yearly progression of HAQ-DI >0.1. We performed a multiple logistic regression analysis to explore the factors predicting HAQ-DI progression at one year. HAQ-DI progression was observed in 18% of the patients. The multiple logistic regression analysis revealed the independent variables associated with HAQ-DI progression were: DAS28-ESR >5.1 at baseline (odds ratio [OR] 0.31, 95% con dence interval [CI] 0.13-0.74, p=0.0083); HAQ-DI score at baseline <0.5 (OR 2.27, 95% CI 1.22-4.26, p=0.0102); and achievement of low disease activity at 12 weeks (OR 0.42, 95% CI 0.21-0.82, p=0.0112). Our data suggest that maintaining clinical improvement according to T2T and initiating the treatment at an early stage are important for functional improvement after one year and that patients with low baseline HAQ scores have a higher risk of HAQ disability progression.

Identifiants

pubmed: 32896260
pii: 14994

Substances chimiques

Antirheumatic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1096-1101

Auteurs

Remi Sumiyoshi (R)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Toshihiko Hidaka (T)

Department of Rheumatology, Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan.

Tomohiro Koga (T)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, and Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. tkoga@nagasaki-u.ac.jp.

Akitomo Okada (A)

Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.

Takaaki Fukuda (T)

Department of Rheumatology, Tenjinkai Koga Hospital 21, Kurume, Japan.

Tomonori Ishii (T)

Department of Haematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.

Yukitaka Ueki (Y)

Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan.

Takao Kodera (T)

Department of Haematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.

Munetoshi Nakashima (M)

Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, and Department of Rheumatology, Kurume University Medical Center, Kurume, Japan.

Yuichi Takahashi (Y)

Yu Family Clinic, Miyagi, Japan.

Seiyo Honda (S)

Department of Rheumatology, Kurume University Hospital, Kurume, Japan.

Yoshiro Horai (Y)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, and Department of General and Internal Medicine, Rheumatology, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.

Ryu Watanabe (R)

Department of Haematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.

Hiroshi Okuno (H)

Department of Orthopaedic Surgery, Tohoku University Hospital, Sendai, Japan.

Toshiyuki Aramaki (T)

Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, and Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan.

Tomomasa Izumiyama (T)

Higashisendai Rheumatic Disease Clinic, Miyagino, Sendai, Japan.

Osamu Takai (O)

Osaki Citizen Hospital, Osaki, Japan.

Taiichiro Miyashita (T)

Department of General and Internal Medicine, Rheumatology, National Hospital Organization, Nagasaki Medical Center, Omura, and Miyashita Rheumatology Clinic, Omura, Japan.

Shin-Ya Kawashiri (SY)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, and Department of Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Naoki Iwamoto (N)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Kunihiro Ichinose (K)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Mami Tamai (M)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Hideki Nakamura (H)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Tomoki Origuchi (T)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, and Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Katsumi Eguchi (K)

Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, and Sasebo City General Hospital, Sasebo, Japan.

Atsushi Kawakami (A)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH